99 / 144
99
diabetic macular edema: two year results from a comparative effectiveness randomized
clinical trial. Ophthalmology. 2016; 123: 1351-1359.
18. Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Diabetic Retino-
pathy Clinical Research Network. Cost-effectiveness of a`ibercept, bevacizumab, and
ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopa-
thy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;
134:888-96.
19. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic
Retinopathy Clinical Research Network. A randomized trial comparing intravitreal
triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.
Ophthalmology. 2008; 115:1447-5.
20. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combi-
nation with laser photocoagulation for the treatment of diffuse diabetic macular ede-
ma.; Ozurdex PLACID Study Group. Ophthalmology. 2013 Sep; 120(9): 1843-51.
21. Campochiaro PA, Brown DM, Pearson A, et al. Long-term bene%t of sustained-delivery
`uocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology.
2011; 118: 626-635.e622
22. Haller J a, Qin H, Apte RS, et al. Vitrectomy outcomes in eyes with diabetic macular
edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087-1093.
23. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus
prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular ede-
ma. Ophthalmology. 2010; 117(6):1064-1077.
DRCR.net.
24. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for
edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010; 117:2146-
2151.
25. Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM. Randomized Trial of
Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular
Edema: TREX-DME 1-Year Outcomes. Ophthalmology. 2017 Jan;124(1):74-81.
26. Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy Clinical Research Network,
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcino-
lone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609-14.
27. Mukkamala L, Bhagat N, Zarbin MA. Practical Lessons from Protocol I for the Manage-
ment of Diabetic Macular Edema. Dev Ophthalmol. 2017; 60:91-108.
28. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (Avastin) injec-
tion alone or combined with triamcinolone versus macular photocoagulation as prima-
ry treatment of diabetic macular edema. Retina.
2007; 27:1187-1195.
29. Aksoy S, Yilmaz G, Akkoyun I, Yazici AC. Comparison of intravitreal bevacizumab and
triamcinolone acetonide therapies for diffuse diabetic macular edema. Int J Ophthal-
mol. 2015; 8(3): 550-555.
30. Chan CKM, Lai TYY, Mohamed S, et al. Combined high-dose sub-tenon triamcinolone,
intravitreal bevacizumab, and laser photocoagulation for refractory diabetic macular
edema: a pilot study. Retina (Philadelphia, Pa.). 2012;32(4):672-8.
31. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal
bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular ede-
ma. Am J Ophthalmol. 2008;145:854-861.
32. Friedman SM, Almukhtar TH, et al. Diabetic Retinopathy Clinical Research Network.
Topical Nepafenac in Eyes with Non-Central Diabetic Macular Edema. Retina (Phila-
delphia, Pa). 2015;35(5):944-956.